Cancer
HT-6184: A Novel Approach to Cancer Treatment
Sophia’s* Day
SAMPLE DAILY EXPERIENCES WITH CANCER
Sophia faces numerous challenges, extending beyond her physical symptoms every day. The emotional toll of cancer is significant; anxiety, fear, and uncertainty about the future are often overwhelming.
Sophia’s daily routines are disrupted by frequent medical appointments, treatments, and their side effects, such as fatigue, nausea, and pain, making even simple tasks feel exhausting. Maintaining a sense of normalcy is difficult as Sophia struggles with hair loss or weight fluctuations and other changes in appearance affecting her self-esteem.
Sophia’s symptoms and treatments limit her ability to participate in activities she once enjoyed, and she often ends up isolated socially. Financial stress from medical bills and the inability to work adds another layer to her burden. Balancing hope with reality is a constant struggle, requiring immense strength and support from loved ones and healthcare providers.
How would Sophia’s life be different without the daily challenge and uncertainty of cancer? Halia is focused on making the answer to that question a reality.
*Names and likenesses are changed to protect patient privacy.
I’m exhausted physically and emotionally. I have hope I can beat cancer, but on my bad days, I wonder if it’s worth the fight.
Cancer
Cancer is a group of diseases marked by uncontrolled cell growth. Chronic inflammation contributes to cancer development and progression, with the tumor microenvironment playing a key role.15 Halia Therapeutics is studying the NLRP3 inflammasome’s role in cancer, particularly its impact on the tumor environment. This component of the innate immune system can promote tumor growth when chronically activated.16 Our investigational compound, HT-6184, targets NLRP3 to modulate inflammation in tumors. Early studies suggest it may reduce pro-tumor inflammation while preserving anti-tumor responses. However, these findings require further clinical validation.Halia’s NLRP3-focused approach represents a novel cancer research strategy. We aim to develop therapies complementing existing treatments by addressing inflammation. As with all our investigational therapies, rigorous clinical trials are necessary to establish safety and efficacy in cancer patients.Obesity
Almost half of US adults are obese or severely obese. Lack of physical activity, unhealthy eating behavior, and, in some cases, genetics contribute to obesity. Halia is developing investigational treatments to combat obesity.
Pain and Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is an autoimmune condition where the immune system—normally the body's defender against infection and disease—attacks its own tissues. This results in pain, swelling, stiffness, and loss of joint function. Halia is developing an investigational treatment for both RA and post-surgical pain.
Alzheimer's Disease
Alzheimer’s disease involves parts of the brain that control memory, language, problem-solving, and other thinking abilities. It can seriously affect a person’s ability to carry out daily activities. Halia is developing a potentially relevant pathway and investigational treatment for Alzheimer’s.
Parkinson's Disease
Parkinson’s disease is a progressive disorder that affects the nervous system and the parts of the body controlled by the nerves. Tremors, stiffness, or slowing of movement are typical symptoms. Halia is developing a potential brain-penetrant compound to treat the disease.